3,3′-Diindolylmethane Protects against Cardiac Hypertrophy via 5′-Adenosine Monophosphate-Activated Protein Kinase-α2

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Zong, Jing ^a,b   Deng, Wei ^a,b   Zhou, Heng ^a,b   Bian, Zhou Yan ^a,b   Dai, Jia ^a,b   Yuan, Yuan ^a,b   Zhang, Jie Yu ^a,b   Zhang, Rui ^a,b   Zhang, Yan ^a,b   Wu, Qing Qing ^a,b   Guo, Hai Peng ^c   Li, Hong Liang ^a,b   Tang, Qi Zhu ^a,b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3,3' DIINDOLYLMETHANE; 5' ADENOSINE MONOPHOSPHATE ACTIVATED PROTEIN KINASE ALPHA2; COLLAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; UNCLASSIFIED DRUG; 3,3'-DIINDOLYLMETHANE; AMPK ALPHA2 SUBUNIT, MOUSE; CARDIOTONIC AGENT; INDOLE DERIVATIVE; S6 KINASE; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CARDIOMEGALY; DRUG EFFECT; ENZYMOLOGY; FIBROSIS; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHOSPHORYLATION;

MAMMALIA; MURINAE; MUS;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CARDIOMEGALY; CARDIOTONIC AGENTS; FIBROSIS; INDOLES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDATIVE STRESS; PHOSPHORYLATION; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

MLCS; MLOWN;

EID: 84872224969     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053427     Document Type: Article

References (34)

1. Gupta S, Das B, Sen S, (2007) Cardiac hypertrophy: mechanisms and therapeutic opportunities. Antioxid Redox Signal 9: 623-652.
2. Barry SP, Davidson SM, Townsend PA, (2008) Molecular regulation of cardiac hypertrophy. Int J Biochem Cell Biol 40: 2023-2039.
3. Balakumar P, Singh AP, Singh M, (2007) Rodent models of heart failure. J Pharmacol Toxicol Methods 56: 1-10.
4. Azmi AS, Ahmad A, Banerjee S, Rangnekar VM, Mohammad RM, et al. (2008) Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3′ diindolylmethane (DIM). Pharm Res 25: 2117-2124.
5. Li Y, Wang Z, Kong D, Murthy S, Dou QP, et al. (2007) Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3′-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J Biol Chem 282: 21542-21550.
6. Xue L, Firestone GL, Bjeldanes LF, (2005) DIM stimulates IFNgamma gene expression in human breast cancer cells via the specific activation of JNK and p38 pathways. Oncogene 24: 2343-2353.
7. Kunimasa K, Kobayashi T, Kaji K, Ohta T, (2010) Antiangiogenic effects of indole-3-carbinol and 3,3′-diindolylmethane are associated with their differential regulation of ERK1/2 and Akt in tube-forming HUVEC. J Nutr 140: 1-6.
8. Cho HJ, Seon MR, Lee YM, Kim J, Kim JK, et al. (2008) 3,3′-Diindolylmethane suppresses the inflammatory response to lipopolysaccharide in murine macrophages. J Nutr 138: 17-23.
9. Shirwany NA, Zou MH, (2010) AMPK in cardiovascular health and disease. Acta Pharmacol Sin 31: 1075-1084.
10. Russell RR, 3rd, Li J, Coven DL, Pypaert M, Zechner C, et al (2004) AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 114: 495-503.
11. Hwang JT, Kwon DY, Park OJ, Kim MS, (2008) Resveratrol protects ROS-induced cell death by activating AMPK in H9c2 cardiac muscle cells. Genes Nutr 2: 323-326.
12. Zhang P, Hu X, Xu X, Fassett J, Zhu G, et al. (2008) AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 52: 918-924.
13. Tian R, Musi N, D′Agostino J, Hirshman MF, Goodyear LJ, (2001) Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 104: 1664-1669.
14. Chen DZ, Qi M, Auborn KJ, Carter TH, (2001) Indole-3-carbinol and diindolylmethane induce apoptosis of human cervical cancer cells and in murine HPV16-transgenic preneoplastic cervical epithelium. J Nutr 131: 3294-3302.
15. Khwaja FS, Wynne S, Posey I, Djakiew D, (2009) 3,3′-diindolylmethane induction of p75NTR-dependent cell death via the p38 mitogen-activated protein kinase pathway in prostate cancer cells. Cancer Prev Res (Phila) 2: 566-571.
16. Li H, He C, Feng J, Zhang Y, Tang Q, et al. (2010) Regulator of G protein signaling 5 protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload. Proc Natl Acad Sci U S A 107: 13818-13823.
17. Bian ZY, Huang H, Jiang H, Shen DF, Yan L, et al. (2010) LIM and cysteine-rich domains 1 regulates cardiac hypertrophy by targeting calcineurin/nuclear factor of activated T cells signaling. Hypertension 55: 257-263.
18. Zhou H, Shen DF, Bian ZY, Zong J, Deng W, et al. (2011) Activating transcription factor 3 deficiency promotes cardiac hypertrophy, dysfunction, and fibrosis induced by pressure overload. PLoS One 6: e26744.
19. Ernst IM, Schuemann C, Wagner AE, Rimbach G, (2011) 3,3′-Diindolylmethane but not indole-3-carbinol activates Nrf2 and induces Nrf2 target gene expression in cultured murine fibroblasts. Free Radic Res 45: 941-949.
20. Hu X, Xu X, Lu Z, Zhang P, Fassett J, et al. (2011) AMP activated protein kinase-alpha2 regulates expression of estrogen-related receptor-alpha, a metabolic transcription factor related to heart failure development. Hypertension 58: 696-703.
21. Heidrich F, Schotola H, Popov AF, Sohns C, Schuenemann J, et al. (2010) AMPK- Activated Protein Kinase and its Role in Energy Metabolism of the Heart. Curr Cardiol Rev 6: 337-342.
22. Viollet B, Horman S, Leclerc J, Lantier L, Foretz M, et al. (2010) AMPK inhibition in health and disease. Crit Rev Biochem Mol Biol 45: 276-295.
23. Jensen TE, Wojtaszewski JF, Richter EA, (2009) AMP-activated protein kinase in contraction regulation of skeletal muscle metabolism: necessary and/or sufficient? Acta Physiol (Oxf) 196: 155-174.
24. Finckenberg P, Mervaala E, (2010) Novel regulators and drug targets of cardiac hypertrophy. J Hypertens 28Suppl 1: S33-38.
25. Tee AR, Blenis J, (2005) mTOR, translational control and human disease. Semin Cell Dev Biol 16: 29-37.
26. Ojamaa K, (2010) Signaling mechanisms in thyroid hormone-induced cardiac hypertrophy. Vascul Pharmacol 52: 113-119.
27. Inoki K, Corradetti MN, Guan KL, (2005) Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37: 19-24.
28. McKinsey TA, Kass DA, (2007) Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov 6: 617-635.
29. Proud CG, (2004) Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy. Cardiovasc Res 63: 403-413.
30. Soesanto W, Lin HY, Hu E, Lefler S, Litwin SE, et al. (2009) Mammalian target of rapamycin is a critical regulator of cardiac hypertrophy in spontaneously hypertensive rats. Hypertension 54: 1321-1327.
31. Berk BC, Fujiwara K, Lehoux S, (2007) ECM remodeling in hypertensive heart disease. J Clin Invest 117: 568-575.
32. Li J, Ichikawa T, Villacorta L, Janicki JS, Brower GL, et al. (2009) Nrf2 protects against maladaptive cardiac responses to hemodynamic stress. Arterioscler Thromb Vasc Biol 29: 1843-1850.
33. Maulik SK, Kumar S, (2012) Oxidative stress and cardiac hypertrophy: a review. Toxicol Mech Methods 22: 359-366.
34. Zhu H, Jia Z, Misra BR, Zhang L, Cao Z, et al. (2008) Nuclear factor E2-related factor 2-dependent myocardiac cytoprotection against oxidative and electrophilic stress. Cardiovasc Toxicol 8: 71-85.